Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors

INTRODUCTION: Apremilast, the first oral targeted treatment for moderate to severe psoriasis, is associated with diarrhea, nausea, and vomiting, which have contributed to treatment discontinuation. This study describes early apremilast discontinuation rates in patients with psoriasis, including a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Lana, Wang, Ching An, Patel, Vardhaman, Davidson, David, Kalirai, Samaneh, Panda, Ankita, Seigel, Lauren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442291/
https://www.ncbi.nlm.nih.gov/pubmed/37517029
http://dx.doi.org/10.1007/s13555-023-00975-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442291/
https://www.ncbi.nlm.nih.gov/pubmed/37517029
http://dx.doi.org/10.1007/s13555-023-00975-3

Ejemplares similares